Copyright
©The Author(s) 2016.
World J Gastroenterol. Nov 14, 2016; 22(42): 9378-9386
Published online Nov 14, 2016. doi: 10.3748/wjg.v22.i42.9378
Published online Nov 14, 2016. doi: 10.3748/wjg.v22.i42.9378
Table 1 Patient characteristics n (%)
Characteristics | Patients |
Sexe | |
Male | 34 (67.3) |
Female | 18 (32.7) |
Age | |
< 80 | 9 (17.0) |
≥ 80 | 43 (83.0) |
Tumor location | |
Colorectal | 34 (65.4) |
Pancreas | 18 (34.6) |
Metastasis | |
≤ 1 | 26 (50.0) |
> 1 | 26 (50.0) |
ECOG performance status | |
[0-1] | 43 (82.7) |
[2-3] | 9 (17.3) |
Comorbidities | |
No | 15 (28.8) |
Yes | 37 (71.2) |
Cardiac comorbidities | |
No | 40 (76.9) |
Yes | 12 (23.1) |
Pulmonary comorbidities | |
No | 47 (90.4) |
Yes | 5 (9.6) |
Hepatic comorbidities | |
No | 52 (100.0) |
Yes | 0 (0.0) |
Albumin level | |
< 30 g/L | 16 (30.8) |
≥ 30 g/L | 21 (40.4) |
Number of usual drugs | |
< 3 | 22 (42.3) |
≥ 4 | 30 (57.7) |
Charlson comorbidities index | |
< 10 | 32 (61.5) |
≥ 10 | 20 (38.5) |
Initial autonomy | |
No | 3 (5.8) |
Yes | 49 (94.2) |
Table 2 Observed toxicity according Common Terminology Criteria for Adverse Events v 4.03 (n = 52) n (%)
CTCAE v 4.03 | ||
All grades | Severe1 | |
Hematological | ||
Anemia | 28 (53.8) | 5 (9.6) |
Neutropenia | 24 (46.2) | 17 (32.7) |
Thrombocytopenia | 14 (26.9) | 3 (5.8) |
Non Hematological | ||
Diarrhea | 35 (67.3) | 13 (25.0) |
Nausea and vomiting | 22 (42.3) | 5 (9.6) |
Asthenia | 49 (94.2) | 5 (9.6) |
Peripheral Neutropenia | 17 (32.7) | 4 (7.7) |
Hepatic toxicity | 4 (7.7) | 1 (1.9) |
Table 3 Univariate and multivariate analysis by subgroup for time under treatment
Univariate analysis | Multivariate analysis | |||||||
HR | 95%CI | P vaule | HR | 95%CI | P vaule | |||
Tumor location | 0.1204 | 0.4288 | ||||||
CR | Ref | Ref | ||||||
Pancréas | 1.615 | 0.882 | 2.958 | 1.316 | 0.667 | 2.599 | ||
Metastatic sites | 0.0478 | 0.1405 | ||||||
0-1 | Ref | Ref | ||||||
≥ 2 | 0.56 | 0.315 | 0.994 | 0.613 | 0.32 | 1.175 | ||
Age | 0.2105 | 0.1637 | ||||||
< 75 | Ref | Ref | ||||||
≥ 75 | 0.692 | 0.389 | 1.231 | 0.664 | 0.373 | 1.182 | ||
Age | 0.371 | |||||||
< 80 | Ref | |||||||
≥ 80 | 1.394 | 0.673 | 2.889 | |||||
Comorbidities | 0.979 | |||||||
No | Ref | |||||||
Yes | 1.008 | 0.549 | 1.851 | |||||
Neoadjuvant chemotherapy | 0.2339 | |||||||
No | Ref | |||||||
Yes | 2.432 | 0.563 | 10.5 | |||||
Initial autonomy (J0) | 0.9059 | |||||||
No | Ref | |||||||
Yes | 0.932 | 0.288 | 3.018 | |||||
Charlson comorbidities index | 0.7659 | |||||||
< 10 | Ref | |||||||
≥ 10 | 0.915 | 0.511 | 1.639 | |||||
ECOG performance status | 0.5046 | |||||||
0-1 | Ref | |||||||
≥ 2 | 1.281 | 0.618 | 2.655 | |||||
Sexe | 0.7228 | |||||||
Male | Ref | |||||||
Female | 0.856 | 0.361 | 2.026 | |||||
Number of usual drugs | 0.3057 | |||||||
< 4 | Ref | |||||||
≥ 4 | 1.34 | 0.765 | 2.347 |
Table 4 Univariate and multivariate analysis by subgroup for overall survival
Univariate analysis | Multivariate analysis | |||||||
HR | 95%CI | P vaule | HR | 95%CI | P vaule | |||
Tumor location | < 10-4 | < 10-4 | ||||||
CR | Ref | Ref | ||||||
Pancréas | 6.362 | 2.963 | 13.66 | 5.816 | 2.47 | 13.693 | ||
Metastatic sites | 0.0634 | 0.9874 | ||||||
0-1 | Ref | Ref | ||||||
≥ 2 | 0.555 | 0.298 | 1.034 | 1.006 | 0.498 | 2.032 | ||
Age | 0.5721 | 0.7614 | ||||||
< 75 | Ref | Ref | ||||||
≥ 75 | 1.184 | 0.659 | 2.124 | 1.096 | 0.607 | 1.976 | ||
Age | 0.5365 | 0.274 | ||||||
< 80 | Ref | Ref | ||||||
≥ 80 | 1.277 | 0.588 | 2.774 | 1.611 | 0.686 | 3.786 | ||
Sexe | 0.1178 | 0.4136 | ||||||
Male | Ref | Ref | ||||||
Female | 0.464 | 0.177 | 1.215 | 0.634 | 0.212 | 1.891 | ||
Comorbidities | 0.0899 | 0.8701 | ||||||
No | Ref | Ref | ||||||
Yes | 1.787 | 0.914 | 3.495 | 1.066 | 0.494 | 2.301 | ||
Initial autonomy | 0.7372 | |||||||
No | Ref | |||||||
Yes | 1.277 | 0.306 | 5.336 | |||||
Charlson comorbidities index | 0.7507 | |||||||
< 10 | Ref | |||||||
≥ 10 | 1.101 | 0.608 | 1.992 | |||||
ECOG performance status | 0.6426 | |||||||
0-1 | Ref | |||||||
≥ 2 | 0.833 | 0.385 | 1.802 | |||||
Number of usual drugs | 0.6116 | |||||||
< 4 | Ref | |||||||
≥ 4 | 1.169 | 0.64 | 2.132 |
- Citation: Guion-Dusserre JF, Bertaut A, Ghiringhelli F, Vincent J, Quipourt V, Marilier S, Tharin Z, Bengrine-Lefevre L. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy. World J Gastroenterol 2016; 22(42): 9378-9386
- URL: https://www.wjgnet.com/1007-9327/full/v22/i42/9378.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i42.9378